Biotech man defends his pounds 1.5m share option profit

Cash gains: Research head at cancer drug group reveals Lloyd's losses 8 Former ad agency chiefs make pounds 10m in multimedia launch

Peter Lewis, head of research and development at British Biotech, yesterday defended his decision to cash in share options just days after the group announced a potential breakthrough in cancer treatment.

Since the news, the shares have soared from pounds 10.43, with one deal going through at pounds 25 last week. Mr Lewis's sale at pounds 17.60 a share netted him a pounds 1.5m profit, with fellow board member James Noble making a further pounds 1.7m from option sales yesterday. The shares closed last night down 110p at pounds 16.08.

Speaking from the company's Oxford base yesterday, Dr Lewis said the options "represented 90 per cent of my financial position and I had to shelter some of my position, as it were. I still think it is a very good company and think the shares will go up further, but I felt I had to protect my position."

Dr Lewis said he had "a very good reason" for raising the cash now as a loss-making name at the Lloyd's of London insurance market. He faces a cash call next year from the new Equitas reinsurance vehicle designed to protect names from huge past losses.

He admitted that the sale "looks unusual", but said that companies like British Biotech were more usual in the US and similar option sales were "a very, very common occurrence" there. He suggested that British Biotech was already looking like US success stories, such as Amgen and Genentech, which had been built up from scratch.

Dr Lewis was previously vice-president of product development at Marion Merrell Dow, a big US pharmaceuticals group. "The fact of the matter is I consider that these options were part of the package which took me to the company in the first place", he said. "I wouldn't have come without them." Dr Lewis claimed they were part of the "entrepreneurial start-up culture" of a company like British Biotech.

Dr Lewis exercised his right to convert 106,695 options at 337p a share. He immediately sold 106,000 at the prevailing market price of pounds 17.60, making a profit of pounds 1.5m on the deal. Mr Noble, finance director, exercised 106,695 at 187p and a further 16,000 at 337p. His sale of 110,000 shares left him with a gain of pounds 1.7m.

The company's shares soared 48 per cent last Thursday, adding pounds 244m to its stock market value, after it announced what may be a breakthrough in the treatment of cancer. One deal in the shares went through at over pounds 26 last week, but since then the share price has fallen back, not helped by the news of directors' dealings.

City analysts have become excited by the prospects for Marimastat, an oral drug which has shown some effectiveness in halting the growth or reducing the size of cancerous tumours in trials. Some estimates have suggested eventual revenues could top $1bn.

However, the results, covering 94 late-stage cancer patients, are only preliminary and the drug has a long way to go before gaining approval from the regulatory authorities. Meanwhile, British Biotech, which was floated at 425p a share in 1992, has yet to show a profit or pay its investors a dividend.

Start your day with The Independent, sign up for daily news emails
Latest stories from i100
Have you tried new the Independent Digital Edition apps?
Independent Dating
and  

By clicking 'Search' you
are agreeing to our
Terms of Use.

iJobs Job Widget
iJobs Money & Business

Guru Careers: Pricing Analyst

£30 - 35k: Guru Careers: We are seeking a Pricing Analyst to join a leading e-...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + OTE £45K YR1: SThree: At SThree, we like to be dif...

SThree: Trainee Recruitment Consultant

£20000 - £25000 per annum + competitive: SThree: Did you know? SThree is a mul...

Guru Careers: C# Project Team Lead

£55 - 65k (DOE): Guru Careers: A unique opportunity for a permanent C# Develop...

Day In a Page

Fifa corruption: The 161-page dossier that exposes the organisation's dark heart

The 161-page dossier that exposes Fifa's dark heart

How did a group of corrupt officials turn football’s governing body into what was, in essence, a criminal enterprise? Chris Green and David Connett reveal all
Mediterranean migrant crisis: 'If Europe thinks bombing boats will stop smuggling, it will not. We will defend ourselves,' says Tripoli PM

Exclusive interview with Tripoli PM Khalifa al-Ghweil

'If Europe thinks bombing boats will stop smuggling, it will not. We will defend ourselves'
Raymond Chandler's Los Angeles: How the author foretold the Californian water crisis

Raymond Chandler's Los Angeles

How the author foretold the Californian water crisis
Chinese artist who posted funny image of President Xi Jinping facing five years in prison as authorities crackdown on dissent in the arts

Art attack

Chinese artist who posted funny image of President Xi Jinping facing five years in prison
Marc Jacobs is putting Cher in the limelight as the face of his latest campaign

Cher is the new face of Marc Jacobs

Alexander Fury explains why designers are turning to august stars to front their lines
Parents of six-year-old who beat leukaemia plan to climb Ben Nevis for cancer charity

'I'm climbing Ben Nevis for my daughter'

Karen Attwood's young daughter Yasmin beat cancer. Now her family is about to take on a new challenge - scaling Ben Nevis to help other children
10 best wedding gift ideas

It's that time of year again... 10 best wedding gift ideas

Forget that fancy toaster, we've gone off-list to find memorable gifts that will last a lifetime
Paul Scholes column: With the Premier League over for another year, here are my end of season awards

Paul Scholes column

With the Premier League over for another year, here are my end of season awards
Heysel disaster 30th anniversary: Liverpool have seen too much tragedy to forget fateful day in Belgium

Liverpool have seen too much tragedy to forget Heysel

Thirty years ago, 39 fans waiting to watch a European Cup final died as a result of a fatal cocktail of circumstances. Ian Herbert looks at how a club dealt with this tragedy
Amir Khan vs Chris Algieri: Khan’s audition for Floyd Mayweather may turn into a no-win situation, says Frank Warren

Khan’s audition for Mayweather may turn into a no-win situation

The Bolton fighter could be damned if he dazzles and damned if he doesn’t against Algieri, the man last seen being decked six times by Pacquiao, says Frank Warren
Blundering Tony Blair quits as Middle East peace envoy – only Israel will miss him

Blundering Blair quits as Middle East peace envoy – only Israel will miss him

For Arabs – and for Britons who lost their loved ones in his shambolic war in Iraq – his appointment was an insult, says Robert Fisk
Fifa corruption arrests: All hail the Feds for riding to football's rescue

Fifa corruption arrests

All hail the Feds for riding to football's rescue, says Ian Herbert
Isis in Syria: The Kurdish enclave still resisting the tyranny of President Assad and militant fighters

The Kurdish enclave still resisting the tyranny of Assad and Isis

In Syrian Kurdish cantons along the Turkish border, the progressive aims of the 2011 uprising are being enacted despite the war. Patrick Cockburn returns to Amuda
How I survived Cambodia's Killing Fields: Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape the US

How I survived Cambodia's Killing Fields

Acclaimed surgeon SreyRam Kuy celebrates her mother's determination to escape to the US
Stephen Mangan interview: From posh buffoon to pregnant dad, the actor has quite a range

How Stephen Mangan got his range

Posh buffoon, hapless writer, pregnant dad - Mangan is certainly a versatile actor